Drug Overlaps, Shortages May Complicate Teva Bid For Mylan
Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.
Both issues will factor into any antitrust review, they said.
Teva, the world’s largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal.
Hey, check out all the research scientist jobs. Post your resume today!
Both issues will factor into any antitrust review, they said.
Teva, the world’s largest generic drugmaker, made its $40 billion offer public on Tuesday and quickly signaled it was ready to sell some overlapping assets to win antitrust approval for a deal.
Hey, check out all the research scientist jobs. Post your resume today!